Near-infrared chemiluminescent probes for in-vivo imaging

US11241507B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11241507-B2
Application numberUS-201816616336-A
CountryUS
Kind codeB2
Filing dateMay 23, 2018
Priority dateMay 24, 2017
Publication dateFeb 8, 2022
Grant dateFeb 8, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides turn-ON dioxetane-based chemiluminescence probes based on the Schapp's adamantylidene-dioxetane probe, which emit light in the near-infrared (NIR) region and are therefore useful for in vivo imaging, as well as compositions and uses thereof.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of the formula Ia or Ib: wherein R 1 is selected from the group consisting of a linear or branched (C 1 -C 18 )alkyl, and (C 3 -C 7 )cycloalkyl; R 2 and R 3 each independently is selected from the group consisting of a branched (C 3 -C 18 )alkyl and (C 3 -C 7 )cycloalkyl, or R 2 and R 3 together with the carbon atom to which they are attached form a fused, spiro or bridged cyclic or polycyclic ring, R 4 is H, or a caging group; L is absent or is a linker of the formula L1, L2 or L3, optionally substituted at the aromatic ring with one or more substituents each independently selected from the group consisting of (C 1 -C 18 )alkyl and (C 3 -C 7 )cycloalkyl, wherein M is absent or is —O— or —NH—, and the asterisk represents the point of attachment to the group Y, provided that M is —O— or —NH— unless R 4 is 4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl or —B(OH) 2 , and when R 4 is H, L is absent; Y is absent or is —O—, provided that Y is —O— unless R 4 is 4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl or —B(OH) 2 , and L is absent; R 5 is H, or represents at least one electron acceptor group such as halogen, —NO 2 , —CN, —COOR 6 , —C(═O)R 6 and —SO 2 R 6 , each independently attached either ortho or para to the —Y-L-R 4 group; R 6 each independently is H or —(C 1 -C 18 )alkyl; and A represents one or two π* acceptor groups, each independently attached either ortho or para to the —Y-L-R 4 group and selected from the group consisting of —CN and —CH═CH-E, wherein E is (a) —CN, —COOH, or —COO(C 1 -C 18 )alkyl optionally interrupted in the alkylene chain with one or more —O— groups; (b) 4-pyridinyl, methylpyridinium-4-yl, 3,3-dimethyl-3H-indolyl, or 1,3,3-trimethyl-3H-indol-1-ium-2-yl, optionally substituted at one or more of the carbon atoms of the aromatic or heteroaromatic ring with a substituent each independently selected from the group consisting of halogen, —CN, —COOH, —COOR, and —C(O)R, wherein R is —(C 1 -C 18 )alkyl; (c) 4-(dicyanomethylene)-4H-chromen-2-yl, 4H-chromen-2-yl-4-one, 9-(dicyanomethylene)-9H-xanthen-3-yl, 9H-xanthen-3-yl-9-one, 2-dicyanomethylenemethyl-thieno[3,2-b]thiophene-5-yl, 3-methylbenzo[d]thiazol-2-yl-3-ium, tetrathiafulvalenyl, 1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl, benzo[d]oxazol-2-yl, benzo[d]thiazol-2-yl, 1H-benzo[d]imidazol-2-yl, 2,6-di-tert-butylpyrylium-4-yl, 1-methylquinolin-1-ium-4-yl, or 4-dicyanomethylene-2-methyl-4H-pyran-6-yl, optionally substituted at one or more of the carbon atoms of the aromatic or heteroaromatic ring with a substituent each independently selected from the group consisting of halogen, —CN, —COOH, —COOR, and —C(O)R, wherein R is —(C 1 -C 18 )alkyl; or (d) 5,5-dimethyl-3-cyano-2-dicyanomethylene-2,5-dihydrofuran-4-yl, or 5,5-dimethyl-3-cyano-2-oxo-2,5-dihydrofuran-4-yl, provided that at least one of said π* acceptor groups is —CH═CH-E, wherein E is selected from groups (c) and (d). 2. The compound of claim 1 , wherein: (i) R 1 is a linear or branched (C 1 -C 8 )alkyl; or (ii) R 2 and R 3 together with the carbon atom to which they are attached form a fused, spiro or bridged polycyclic ring; or (iii) said caging group is selected from the group consisting of: wherein Pep is a group comprising a peptide moiety consisting of at least two amino acid residues and linked to the aniline group via a carboxylic group of said peptide moiety; or (iv) R 5 is H, or an electron acceptor group selected from the group consisting of halogen and —CN, attached either ortho or para to the —Y-L-R 4 group. 3. The compound of claim 2 , wherein R 2 and R 3 together with the carbon atom to which they are attached form adamantyl. 4. The compound of claim 2 , wherein R 5 is halogen or —CN, attached ortho to the —Y-L-R 4 group. 5. The compound of claim 1 , wherein A represents one or two π* acceptor groups, wherein: (i) one of said π* acceptor groups is of the formula —CH═CH-E, wherein E is (a) 4-(dicyanomethylene)-4H-chromen-2-yl, 4H-chromen-2-yl-4-one, 9-(dicyanomethylene)-9H-xanthen-3-yl, 9H-xanthen-3-yl-9-one, 2-dicyanomethylenemethyl-thieno[3,2-b]thiophene-5-yl, 3-methylbenzo[d]thiazol-2-yl-3-ium, tetrathiafulvalenyl, 1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl, benzo[d]oxazol-2-yl, benzo[d]thiazol-2-yl, 1H-benzo[d]imidazol-2-yl, 2,6-di-tert-butylpyrylium-4-yl, 1-methylquinolin-1-ium-4-yl, or 4-dicyanomethylene-2-methyl-4H-pyran-6-yl, optionally substituted at one or more of the carbon atoms of the aromatic or heteroaromatic ring; or (b) 5,5-dimethyl-3-cyano-2-dicyanomethylene-2,5-dihydrofuran-4-yl, or 5,5-dimethyl-3-cyano-2-oxo-2,5-dihydrofuran-4-yl; and (ii) the other one of said π* acceptor groups, when present, is of the formula —CH═CH-E, wherein E is —CN, —COOH, or —COO(C 1 -C 18 )alkyl optionally interrupted in the alkylene chain with one or more —O— groups. 6. The compound of claim 5 , wherein: (i) one of said π* acceptor groups is of the formula —CH═CH-E, wherein E is 4-(dicyanomethylene)-4H-chromen-2-yl optionally substituted at one or more of the carbon atoms of the aromatic or heteroaromatic ring, or 5,5-dimethyl-3-cyano-2-dicyanomethylene-2,5-dihydrofuran-4-yl; and (ii) the other one of said π* acceptor groups, when present, is of the formula —CH═CH-E, wherein E is —CN, —COOH, or —COO(C 1 -C 18 )alkyl optionally interrupted in the alkylene chain with one or more —O— groups. 7. The compound of claim 1 , wherein: R 1 is a linear or branched (C 1 -C 8 )alkyl; R 2 and R 3 together with the carbon atom to which they are attached form a fused, spiro or bridged polycyclic ring; R 5 is H, or an electron acceptor group selected from the group consisting of halogen and —CN, attached either ortho or para to the —Y-L-R 4 group; and A represents one or two π* acceptor groups, wherein (i) one of said π* acceptor groups is of the formula —CH═CH-E, wherein E is (a) 4-(dicyanomethylene)-4H-chromen-2-yl, 4H-chromen-2-yl-4-one, 9-(dicyanomethylene)-9H-xanthen-3-yl, 9H-xanthen-3-yl-9-one, 2-dicyanomethylenemethyl-thieno[3,2-b]thiophene-5-yl, 3-methylbenzo[d]thiazol-2-yl-3-ium, tetrathiafulvalenyl, 1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl, benzo[d]oxazol-2-yl, benzo[d]thiazol-2-yl, 1H-benzo[d]imidazol-2-yl, 2,6-di-tert-butylpyrylium-4-yl, 1-methylquinolin-1-ium-4-yl, or 4-dicyanomethylene-2-methyl-4H-pyran-6-yl, optionally substituted at one or more of the carbon atoms of the aromatic or heteroaromatic ring; or (b) 5,5-dimethyl-3-cyano-2-dicyanomethylene-2,5-dihydrofuran-4-yl, or 5,5-dimethyl-3-cyano-2-oxo-2,5-dihydrofuran-4-yl; and (ii) the other one of said π* acceptor groups, when present, is of the formula —CH═CH-E, wherein E is —CN, —COOH, or —COO(C 1 -C 18 )alkyl optionally interrupted in the alkylene chain with one or more —O— groups. 8. The compound of claim 7 , wherein: R 1 is methyl, ethyl, or isopropyl; R 2 and R 3 together with the carbon atom to which they are attached form adamantyl; R 5 is H, or is an electron acceptor group selected from the group consisting of halogen and —CN, attached ortho to the —Y-L-R 4 group; and A represents one or two π* acceptor groups, wherein one of said π* acceptor groups is of the formula —CH═CH-E, wherein E is 4-(dicyanomethylene)-4H-chromen-2-yl, or 5,5-dimethyl-3-cyano-2-dicyanomethylene-2,5-dihydrofuran-4-yl; and the other one of said π* acceptor groups, when p

Assignees

Inventors

Classifications

  • the ethylene chain carrying an heterocyclic residue, e.g. heterocycle-CH=CH-C6H5 · CPC title

  • containing —CHO groups · CPC title

  • linked by a carbon chain containing aromatic rings · CPC title

  • containing organic luminescent materials · CPC title

  • the fluorescent group being a small organic molecule · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11241507B2 cover?
The present invention provides turn-ON dioxetane-based chemiluminescence probes based on the Schapp's adamantylidene-dioxetane probe, which emit light in the near-infrared (NIR) region and are therefore useful for in vivo imaging, as well as compositions and uses thereof.
Who is the assignee on this patent?
Univ Ramot
What technology area does this patent fall under?
Primary CPC classification A61K49/0021. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).